<DOC>
	<DOC>NCT02640664</DOC>
	<brief_summary>The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301</brief_summary>
	<brief_title>Rainbow Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy of Prematurity</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>The patient successfully completed the core study CRFB002H2301 The patient received study treatment in both eyes at baseline of study CRFB002H2301 Patient has a medical condition or personal circumstance which precludes study participation or compliance with study procedures, as assessed by the Investigator Patient has been discontinued from the core study CRFB002H2301 at any time Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>open-label, long-term, extension study</keyword>
	<keyword>intravitreal ranibizumab</keyword>
	<keyword>laser ablation therapy</keyword>
	<keyword>retinopathy of prematurity</keyword>
	<keyword>preterm infants</keyword>
	<keyword>RAINBOW</keyword>
</DOC>